3B Blackbio Dx
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
3B BlackBio Dx scheduled a virtual one-on-one investor conference call with Marcellus Investment Managers for 16 September 2026 at 11:00 a.m. India time. The meeting was listed as a single-institution interaction, and the company said only information available in the public domain would be discussed. The discussion was to use the company's Q1 FY27 investor presentation, which reported Coris revenue of €796,000 and an EBITDA loss of €325,000, alongside 38% growth in exports. For FY26, consolidated revenue was ₹141.92 crore, of which diagnostics contributed ₹131.12 crore.
Powered by Tijori
3B BlackBio Dx scheduled a virtual one-on-one investor conference call with Marcellus Investment Managers for 16 September 2026 at 11:00 a.m. India time. The meeting was listed as a single-institution interaction, and the company said only information available in the public domain would be discussed. The discussion was to use the company's Q1 FY27 investor presentation, which reported Coris revenue of €796,000 and an EBITDA loss of €325,000, alongside 38% growth in exports. For FY26, consolidated revenue was ₹141.92 crore, of which diagnostics contributed ₹131.12 crore.
Powered by Tijori
3B BlackBio Dx issued an August investor presentation covering its agrochemicals and molecular-diagnostics businesses and first-quarter performance for FY2026-27. Consolidated revenue from operations was ₹33.49 crore and profit after tax was ₹8.98 crore, including Coris BioConcept's ₹8.63 crore sales and negative EBITDA of ₹3.52 crore. Coris confirmed a EUR 1.41 million HAT order for delivery in December 2026 under a EUR 6 million Belgian government contract, and received IVDR certification for two main AMR products. The group completed its acquisition of Coris in August 2025 and reported FY2026 consolidated revenue of ₹141.92 crore, with molecular diagnostics accounting for about 92% of revenue.
Powered by Tijori
3B BlackBio Dx issued an August investor presentation covering its agrochemicals and molecular-diagnostics businesses and first-quarter performance for FY2026-27. Consolidated revenue from operations was ₹33.49 crore and profit after tax was ₹8.98 crore, including Coris BioConcept's ₹8.63 crore sales and negative EBITDA of ₹3.52 crore. Coris confirmed a EUR 1.41 million HAT order for delivery in December 2026 under a EUR 6 million Belgian government contract, and received IVDR certification for two main AMR products. The group completed its acquisition of Coris in August 2025 and reported FY2026 consolidated revenue of ₹141.92 crore, with molecular diagnostics accounting for about 92% of revenue.
Powered by Tijori
Jan 3 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
3B BLACKBIO DX - GOT TAX ORDER FOR DEMAND OF 44.6 MILLION RUPEES
Source text: ID:nBSE2zRtzQ
Further company coverage: 3BBL.BO
(([email protected];))
Jan 3 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
3B BLACKBIO DX - GOT TAX ORDER FOR DEMAND OF 44.6 MILLION RUPEES
Source text: ID:nBSE2zRtzQ
Further company coverage: 3BBL.BO
(([email protected];))
Sept 17 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
3B BLACKBIO DX LTD - RECEIVED AN ORDER WORTH 13.7 MILLION RUPEES
Source text for Eikon: ID:nBSE7r4ndC
Further company coverage: 3BBL.BO
(([email protected];;))
Sept 17 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
3B BLACKBIO DX LTD - RECEIVED AN ORDER WORTH 13.7 MILLION RUPEES
Source text for Eikon: ID:nBSE7r4ndC
Further company coverage: 3BBL.BO
(([email protected];;))
Jan 10 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
GETS EXPORT ORDER WORTH $192,800
Further company coverage: 3BBL.BO
(([email protected];))
Jan 10 (Reuters) - 3B Blackbio DX Ltd 3BBL.BO:
GETS EXPORT ORDER WORTH $192,800
Further company coverage: 3BBL.BO
(([email protected];))
Aug 8 (Reuters) - Kilpest India Ltd KILP.BO:
NATIONAL COMPANY LAW TRIBUNAL APPROVED SCHEME OF AMALGAMATION BETWEEN 3B BLACKBIO BIOTECH INDIA KILPEST INDIA
Source text for Eikon: ID:nBSE5dwMgM
Further company coverage: KILP.BO
(([email protected];;))
Aug 8 (Reuters) - Kilpest India Ltd KILP.BO:
NATIONAL COMPANY LAW TRIBUNAL APPROVED SCHEME OF AMALGAMATION BETWEEN 3B BLACKBIO BIOTECH INDIA KILPEST INDIA
Source text for Eikon: ID:nBSE5dwMgM
Further company coverage: KILP.BO
(([email protected];;))
May 29 (Reuters) - Kilpest India Ltd KILP.BO:
KILPEST INDIA LTD - FINAL DIVIDEND 2.5 RUPEES PER SHARE
Source text for Eikon: ID:nBSE84l8Df
Further company coverage: KILP.BO
(([email protected];))
May 29 (Reuters) - Kilpest India Ltd KILP.BO:
KILPEST INDIA LTD - FINAL DIVIDEND 2.5 RUPEES PER SHARE
Source text for Eikon: ID:nBSE84l8Df
Further company coverage: KILP.BO
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does 3B Blackbio Dx do?
Established in 1972, KILPEST is a leading Agri-based company in India. Initially the only pesticide formulating company in Madhya Pradesh, it has grown to manufacture 50 pesticide products, microfertilizers, biofertilizers, and biopesticides in Central India.
Who are the competitors of 3B Blackbio Dx?
3B Blackbio Dx major competitors are TTK Healthcare, Nureca, QMS Medi Allied Ser., Poly Medicure, Amrutanjan Health., Health X Platform, Max India. Market Cap of 3B Blackbio Dx is ₹1,222 Crs. While the median market cap of its peers are ₹975 Crs.
Is 3B Blackbio Dx financially stable compared to its competitors?
3B Blackbio Dx seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does 3B Blackbio Dx pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. 3B Blackbio Dx latest dividend payout ratio is 7.19% and 3yr average dividend payout ratio is 7.82%
How has 3B Blackbio Dx allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is 3B Blackbio Dx balance sheet?
Balance sheet of 3B Blackbio Dx is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of 3B Blackbio Dx improving?
Yes, profit is increasing. The profit of 3B Blackbio Dx is ₹56.26 Crs for TTM, ₹47.69 Crs for Mar 2025 and ₹32.1 Crs for Mar 2024.
Is the debt of 3B Blackbio Dx increasing or decreasing?
Yes, The net debt of 3B Blackbio Dx is increasing. Latest net debt of 3B Blackbio Dx is -₹97.51 Crs as of Mar-26. This is greater than Mar-25 when it was -₹137.25 Crs.
Is 3B Blackbio Dx stock expensive?
Yes, 3B Blackbio Dx is expensive. Latest PE of 3B Blackbio Dx is 22.01, while 3 year average PE is 21.54. Also latest EV/EBITDA of 3B Blackbio Dx is 21.03 while 3yr average is 18.55.
Has the share price of 3B Blackbio Dx grown faster than its competition?
3B Blackbio Dx has given better returns compared to its competitors. 3B Blackbio Dx has grown at ~33.48% over the last 3yrs while peers have grown at a median rate of 1.26%
Is the promoter bullish about 3B Blackbio Dx?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 40.95% and last quarter promoter holding is 40.94%.
Are mutual funds buying/selling 3B Blackbio Dx?
There is Insufficient data to gauge this.